CAPRICOR THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M | $244,898 |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M | -$20.9M |
| Operating expenses | $108.1M | $64.8M | $49.3M | $32.2M | $21.2M |
| Cash from operations | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M |
| Capital expenditure | $2.9M | $1.2M | $1.3M | $2.0M | $1.2M |
| Free cash flow | -$72.7M | -$41.2M | -$26.9M | $2.9M | -$18.0M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $355.9M | $170.5M | $58.7M | $50.1M | $41.3M |
| Total liabilities | $50.2M | $25.0M | $36.1M | $38.3M | $10.0M |
Shares outstanding 57.9M · Free float 42.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.